Podcast
Questions and Answers
What is the purpose of using horse immunoglobulin ATGAM® in renal transplant patients?
What is the purpose of using horse immunoglobulin ATGAM® in renal transplant patients?
- To prevent allergic reactions
- To reduce circulated T-lymphocytes (correct)
- To improve humoral-mediated immunities
- To enhance cell-mediated immunities
What is the most serious reaction that could occur with animal immunoglobulin therapy?
What is the most serious reaction that could occur with animal immunoglobulin therapy?
- Itching
- Fever
- Erythema
- Anaphylaxis (correct)
How should infusion be managed if anaphylaxis occurs during animal immunoglobulin therapy?
How should infusion be managed if anaphylaxis occurs during animal immunoglobulin therapy?
- Decrease the infusion rate
- Stop the infusion immediately (correct)
- Switch to a different animal immunoglobulin
- Increase the dosage
Which antibody is used to remove cytotoxic T cells responsible for graft rejection in kidney transplantation?
Which antibody is used to remove cytotoxic T cells responsible for graft rejection in kidney transplantation?
What is the recommended action before treating a patient with specific animal immunoglobulins like horse immunoglobulin ATGAM®?
What is the recommended action before treating a patient with specific animal immunoglobulins like horse immunoglobulin ATGAM®?
What should be done if other reactions like chills, fever, itching, and erythema occur during animal immunoglobulin therapy?
What should be done if other reactions like chills, fever, itching, and erythema occur during animal immunoglobulin therapy?
What is the primary source of human immunoglobulins used as drugs?
What is the primary source of human immunoglobulins used as drugs?
Which of the following is NOT a correct application of human immunoglobulins obtained from the general population?
Which of the following is NOT a correct application of human immunoglobulins obtained from the general population?
What is the typical route of administration for human immunoglobulin solutions obtained from healthy donors?
What is the typical route of administration for human immunoglobulin solutions obtained from healthy donors?
What is the approximate half-life of intravenous immunoglobulin solutions in the patient's blood?
What is the approximate half-life of intravenous immunoglobulin solutions in the patient's blood?
Which type of human immunoglobulin solutions are specifically used for postexposure prophylaxis or preventive treatment before hepatitis B vaccination?
Which type of human immunoglobulin solutions are specifically used for postexposure prophylaxis or preventive treatment before hepatitis B vaccination?
What is the term used for the use of human immunoglobulin solutions for the prevention of either general or specific infections?
What is the term used for the use of human immunoglobulin solutions for the prevention of either general or specific infections?
What percentage of rejection can be reversed with OKT3® treatment compared to conventional immunosuppressive treatment?
What percentage of rejection can be reversed with OKT3® treatment compared to conventional immunosuppressive treatment?
In which type of transplantation are anti-T cell monoclonal antibodies used as an ex vivo treatment?
In which type of transplantation are anti-T cell monoclonal antibodies used as an ex vivo treatment?
What is the purpose of using anti-T cell monoclonal antibodies in heterologous transplantations?
What is the purpose of using anti-T cell monoclonal antibodies in heterologous transplantations?
What is one of the most common reactions in using monoclonal antibodies for the treatment of human diseases?
What is one of the most common reactions in using monoclonal antibodies for the treatment of human diseases?
When does the reaction of developing HAMA usually occur after the initial treatment with monoclonal antibodies?
When does the reaction of developing HAMA usually occur after the initial treatment with monoclonal antibodies?
What are the two technologies currently being developed to minimize the problems associated with the formation of HAMA in monoclonal antibody-treated patients?
What are the two technologies currently being developed to minimize the problems associated with the formation of HAMA in monoclonal antibody-treated patients?
